All In Biotech

Drug Trial Radar · NCT05254002

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes

A Parallel-group Treatment, Phase 2, Double-blind, Three-arm Study to Assess Efficacy and Safety of Finerenone Plus Empagliflozin Compared With Either Finerenone or Empagliflozin Alone in Participants With Chronic Kidney Disease and Type 2 Diabetes.

Last checked: Nov 20, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,664 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,664

Actual

Start

Jun 23, 2022

Primary completion

Mar 14, 2025

Study completion Mar 17, 2025

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Feb 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known to trigger injury and inflammation in the kidney and is therefore thought to play a role in CKD. Empagliflozin lowers blood sugar levels by increasing the excretion of glucose from the blood into the urine. In this study, the researchers want to learn how well the combination of finerenone and empagliflozin helps to slow down the worsening of the participants' kidney function compared to either treatment alone. For this, the level of protein in the urine will be measured. The investigators also want to know how safe the combination is compared to either treatment alone. Depending on the treatment group, the participants will either take the combination of finerenone and empagliflozin, or finerenone together with a placebo, or empagliflozin together with a placebo, once a day as tablets by mouth. A placebo looks like a treatment but does not have any medicine in it. Importantly, the participants will also continue to take their other current medicine for CKD and T2D. The participants will be in the study for up to 7.5 months and will take the study treatments for 6 months. During the study, participants will visit the study site 7 times. The study team will: * collect blood and urine samples * check the participants' vital signs * do a physical examination including height and weight * check the participants' heart health by using an electrocardiogram (ECG) * monitor the participants' blood pressure * ask the participants questions about how they are feeling and what adverse events they may be having An adverse event is any problem that happens during the trial. Doctors keep track of all events that happen in trials, even if they do not think the events might be related to the study treatments.

Conditions

  • Type 2 Diabetes Mellitus
  • Chronic Kidney Disease

Interventions

  • Finerenone (BAY94-8862 ) 10 mgDrug

    oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: \<60 mL/min/1.73 m2

  • EmpagliflozinDrug

    oral administration, once daily

  • Empagliflozin PlaceboDrug

    Matching placebo to empagliflozin oral administration, once daily

  • Finerenone (BAY94-8862 ) 20 mgDrug

    oral administration, once daily if screening eGFR (Estimated glomerular filtration rate) results are: ≥60 mL/min/1.73 m2

  • Finerenone PlaceboDrug

    Matching Placebo to Finerenone oral administration once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at Day 180 Relative to Baseline in the Combination Therapy Group Versus Empagliflozin AloneTime frame: Baseline and Day 180
  2. Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) at Day 180 Relative to Baseline in the Combination Therapy Group Versus Finerenone AloneTime frame: Baseline and Day 180

Locations

173 sites in 14 countries. Site status is shown where the registry gives one.

  • Southwest Kidney Institute, PLC - Suprise

    Surprise, Arizona

  • Academic Medical Research Institute

    Los Angeles, California

  • Dignity Health Northridge Hospital Medical Center - Nephrology

    Northridge, California

  • Olive View - UCLA Medical Center

    Sylmar, California

  • Touro University California - Metabolic Research Center

    Vallejo, California

  • Florida Kidney Physicians - Delray Beach Nephrology

    Delray Beach, Florida

  • West Orange Endocrinology & Clinical Research

    Ocoee, Florida

  • Innovative Research Institute

    Port Charlotte, Florida

  • Metabolic Research Institute, Inc.

    West Palm Beach, Florida

  • Grady Memorial Hospital - Endocrinology

    Atlanta, Georgia

  • Southeast Kidney Associates - East Point

    East Point, Georgia

  • Velocity Clinical Research - Savannah

    Savannah, Georgia

  • Nola Care Clinical Research

    Metairie, Louisiana

  • Omega Clinical Research - Metairie

    Metairie, Louisiana

  • South Shore Nephrology

    Plymouth, Massachusetts

  • Lake Michigan Nephrology

    Saint Joseph, Michigan

  • Oakland Medical Research

    Troy, Michigan

  • Clinical Research Consultants, a JCCT Company

    Kansas City, Missouri

  • Kansas City VA Medical Center - Endocrinology

    Kansas City, Missouri

  • Center for Advanced Medicine - Diabetes Center

    St Louis, Missouri

  • St. Louis Heart and Vascular, PC - Christian Hospital Office

    St Louis, Missouri

  • Somnos Clinical Research

    Lincoln, Nebraska

  • Healor Primary Care / CCT Research

    Las Vegas, Nevada

  • CCT Research - Santa Rosa Medical Centers of Nevada

    Las Vegas, Nevada

  • Circuit Clinical/Crystal Run

    Middletown, New York

  • Randolph Health Internal Medicine in Asheboro

    Asheboro, North Carolina

  • UNC Hospitals Outpatient Center at Eastowne - Nephrology

    Chapel Hill, North Carolina

  • Eastern Nephrology Associates - Greenville West

    Greenville, North Carolina

  • Blue Sky, MD/ Lamond Family Medicine

    Hendersonville, North Carolina

  • Eastern Nephrology Associates - Kinston

    Kinston, North Carolina

  • Velocity Clinical Research - Blue Ash

    Cincinnati, Ohio

  • Dunes Clinical Research LLC

    Dakota Dunes, South Dakota

  • DarSalud Care / LifeDOC Research

    Memphis, Tennessee

  • The University of Tennessee Health Science Center - Medical Center Clinic - Nephrology

    Memphis, Tennessee

  • Office of Osvaldo A. Brusco, MD

    Corpus Christi, Texas

  • Thyroid, Endocrinology, and Diabetes - Dallas

    Dallas, Texas

  • DaVita Clinical Research- El Paso

    El Paso, Texas

  • Global Kidney Center

    Houston, Texas

  • Victorium Clinical Research

    Houston, Texas

  • North Texas Kidney Disease Associates Lewisville

    Lewisville, Texas

Showing 40 of 173 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.